A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India

Inclusion Criteria:

• Male or female participants aged >= 65 years of age

• Participants and/or legally acceptable representative (s) (LAR) who in the opinionof the Investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits

• Written or witnessed/thumb printed informed consent obtained from the participantand/or participant's LAR(s) after the study has been explained according to thelocal authority requirements and prior to performance of any study-specificprocedure

Exclusion Criteria:

• History of severe allergic reactions (e.g., anaphylaxis) to any component of thevaccine, including egg protein, or following a previous dose of any influenzavaccine.

• Receipt of licensed vaccine, immune sera and/or any blood products, or aninvestigational trial agent within previous 30 days or planned during theirparticipation in the trial.

• Receipt of any flu vaccine within 6 months before trial start or any other vaccinewithin 30 days before the trial.

• Receipt of any dose of a Coronavirus Disease 2019 (COVID-19) vaccine within 15 daysof trial start.

• History of Guillain-Barré Syndrome.

• Altered immune status or chronic administration (defined as more than 14 days) ofimmunosuppressants or other immune-modifying agents within six months prior toadministration of trial vaccine.

• History of acute infectious disease or acute respiratory illness needing antibioticsor antivirals in the previous 7 days, based on investigator's judgement.

• If a participant candidate has fever, the trial vaccination should be postponed towhen the fever has resolved for at least 2 days (temporary exclusion criterion).Fever is defined as temperature >=38.0 degree Celsius (°C) (100.4 degrees Fahrenheit [°F]) by any route. The preferred location for measuring temperature will be oralroute.

• Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, or renalfunctional abnormality, as determined by medical history, physical examination, orlaboratory screening tests.

• Any other clinical condition that, in the opinion of the investigator, might poseadditional risk to the participant due to participation in the trial.